Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 4, 2010, Pages 497-502

  Rallidis, Loukianos S ^a   Gialeraki, Argyri ^a   Merkouri, Efrosyni ^a   Liakos, George ^b   Dagres, Nikolaos ^a   Sionis, Dimitrios ^c   Travlou, Anthi ^a   Lekakis, John ^a   Kremastinos, Dimitrios T ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

^c 1st IKA Hospital   (Greece)

Author keywords

4G 5G polymorphism of PAI 1; Premature myocardial infarction; Risk factors

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGE; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SURVIVOR; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; HEART INFARCTION; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ADULT; ALLELES; FEMALE; HOMOZYGOTE; HUMANS; LIPOPROTEIN(A); MALE; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77955507113     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0398-z     Document Type: Article

References (43)

1. Voetsch B, Loscalzo J (2004) Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 24:216-229
2. Zimmerman FH, Cameron A, Fisher LD, Ng G (1995) Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 26:654-661
3. Glueck CJ, Munjal J, Aregawi D, Agloria M, Winiarska M, Khalil Q, Wang P (2007) Thrombophilia-hypofibrinolysis and atherothrombotic cardiovascular disease ≤ age 45 years. Transl Res 150:93-100
4. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M (1999) Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 94:46-51
5. Rallidis LS, Belesi CI, Manioudaki HS, Chatziioakimidis VK, Fakitsa VC, Sinos LE, Laoutaris NP, Apostolou TS (2003) Myocardial infarction under the age of 36: prevalence of thrombophilic disorders. Thromb Haemost 90:272-278
6. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3-9
7. Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792-1801
8. Vaughan DE, PAI-1, atherothrombosis (2005) J Thromb Haemost 3:1879-1883
9. van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ (1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72:1467-1473
10. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S (2004) Platelets synthesize large amounts of active plasminogen activator inhibitor
11. Blood 104:3943-3948
12. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D (1988) Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G
13. Thromb Haemost 60:491-494
14. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739-10745
15. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP et al. (1995) The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Myocarde. Thromb Haemost 74:837-841
16. Onalan O, Balta G, Oto A, Kabakci G, Tokgozoglu L, Aytemir K, Altay C, Gurgey A, Nazli N (2008) Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease. J Thromb Thrombolysis 26:211-217
17. Fu L, Jin H, Song K, Zhang C, Shen J, Huang Y (2001) Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction. Chin Med J (Engl) 114:266-269
18. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ (1997) Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 17:33-37
19. Mikkelsson J, Perola M, Wartiovaara U, Peltonen L, Palotie A, Penttilä A, Karhunen PJ (2000) Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb Haemost 84:78-82
20. Zhan M, Zhou Y, Han Z (2003) Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J (Engl) 116:1707-1710
21. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, Davis BP (1999) Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 34:1778-1783
22. Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, Rodondi N, Li R, Zmuda JM, Harris TB (2006) Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 152:1109-1115
23. Doggen CJ, Bertina RM, Cats VM, Reitsma PH, Rosendaal FR (1999) The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 82:115-120
24. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, Sharrett AR, Tracy RP (2003) Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost 1:1799-1804
25. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP (1997) Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95:59-62
26. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ (2001) Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 104:3063-3068
27. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66, 155 cases and 91, 307 controls. Lancet 367:651-658
28. Junker R, Heinrich J, Schulte H, Tataru M, Köhler E, Schönfeld R, Nowak-Göttl U, Assmann G (1998) Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men. Blood Coagul Fibrinolysis 9:597-602
29. Thrombosis Atherosclerosis Vascular Biology Italian Study Group (2003) No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 107:1117-1122
30. Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855
31. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP (2002) The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9:131-137
32. Isordia-Salas I, Leaños-Miranda A, Sainz IM, Reyes-Maldonado E, Borrayo-Sánchez G (2009) Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients. Rev Esp Cardiol 62:365-372
33. Nomenclature and criteria for diagnosis of ischemic heart disease (1979) Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 59:607-609
34. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
35. Schneider DJ, Hayes M, Wadsworth M, Taatjes H, Rincón M, Taatjes DJ, Sobel BE (2004) Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1). J Histochem Cytochem 52:1091-1099
36. Redmond EM, Cullen JP, Cahill PA, Sitzmann JV, Stefansson S, Lawrence DA, Okada SS (2001) Endothelial cells inhibit flowinduced smooth muscle cell migration: role of plasminogen activator inhibitor
37. Circulation 103:597-603
38. Incalcaterra E, Hoffmann E, Averna MR, Caimi G (2004) Genetic risk factors in myocardial infarction at young age. Minerva Cardioangiol 52:287-312
39. Rallidis LS, Gialeraki A, Komporozos C, Vavoulis P, Pavlakis G, Travlou A, Lekakis I, Kremastinos DT (2008) Role of methylenetetrahydrofolate reductase 677C->T polymorphism in the development of premature myocardial infarction. Atherosclerosis 200:115-120
40. Rallidis LS, Politou M, Komporozos C, Panagiotakos DB, Belessi CI, Travlou A, Lekakis J, Kremastinos DT (2008) Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 99:1085-1089
41. Jovin IS, Müller-Berghaus G (2004) Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis. Atherosclerosis 174:225-233
42. Loscalzo J, Weinfeld M, Fless GM, Scanu AM (1990) Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 10:240-245
43. Undas A, Stepien E, Tracz W, Szczeklik A (2006) Lipoprotein (a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 4:973-975